No services found
No Products found
100ug, 1MG
ProteoGenix
Ig (H-gamma4_L-kappa)_G4hCH2CH3
Primary Antibodies
Monoclonal Antibody
XtenCHO
Imelciment Biosimilar is a cutting-edge therapeutic antibody that has been specifically designed to target Vixticibart, a protein that has been identified as a potential therapeutic target for various diseases. This biosimilar is a highly effective and safe treatment option that has shown promising results in pre-clinical and clinical studies.
Imelciment Biosimilar is a monoclonal antibody, which means it is a copy of a naturally occurring antibody produced by a single type of immune cell. It is a large protein molecule composed of two heavy chains and two light chains, connected by disulfide bonds. The antibody has a Y-shaped structure with two antigen-binding sites at the tips of the arms, allowing it to bind specifically to its target, Vixticibart.
The main mechanism of action of Imelciment Biosimilar is to bind to Vixticibart and block its activity, thereby preventing its harmful effects. Vixticibart is a key player in various disease processes, including cancer, autoimmune disorders, and inflammatory diseases. By targeting Vixticibart, Imelciment Biosimilar inhibits its function and helps to restore normal cellular activity, leading to improved health outcomes.
Moreover, Imelciment Biosimilar also has an immune-modulating effect, which means it can regulate the activity of the immune system. This is particularly beneficial in autoimmune disorders, where the immune system mistakenly attacks healthy cells and tissues. By modulating the immune response, Imelciment Biosimilar can help to reduce inflammation and tissue damage, providing relief to patients suffering from autoimmune diseases.
Imelciment Biosimilar has a wide range of potential applications in the field of medicine. It is currently being investigated for its efficacy in various diseases, including cancer, rheumatoid arthritis, psoriasis, and multiple sclerosis. In pre-clinical studies, Imelciment Biosimilar has shown promising results in inhibiting tumor growth and reducing disease activity in autoimmune disorders.
Furthermore, Imelciment Biosimilar has the potential to be used as a therapeutic agent for the treatment of Vixticibart-related diseases, such as Vixticibart-associated lymphoproliferative disorders and Vixticibart-induced cytokine release syndrome. This makes it a versatile and valuable treatment option for a wide range of medical conditions.
In addition to its therapeutic potential, Imelciment Biosimilar is also available in a research grade form for use in laboratory studies. This allows researchers to further explore the mechanism of action and potential applications of this therapeutic antibody. The research grade Imelciment Biosimilar is produced using the same high-quality manufacturing processes as the clinical grade version, ensuring consistency and reliability in research studies.
In summary, Imelciment Biosimilar is a revolutionary therapeutic antibody that targets Vixticibart, a protein involved in various disease processes. Its unique structure and mode of action make it a highly effective and safe treatment option for a wide range of medical conditions. With ongoing research and development, Imelciment Biosimilar has the potential to significantly improve the lives of patients suffering from Vixticibart-related diseases and beyond.
Reviews
There are no reviews yet.
Your email address will not be published. Required fields are marked *
In which application did you use the antibody? * WB ELISA Sandwich ELISA IF IHC IP FC other
Did it work in your application? * Yes No
Your review *
Name *
Email *
Save my name, email, and website in this browser for the next time I comment.
Send us a message from the form below
First name
Last name
Email address
Lab / Company
Phone number
Message
send
Your cart is currently empty.